Theseus Pharmaceuticals I... (THRX)
NASDAQ: THRX
· Real-Time Price · USD
4.07
0.01 (0.25%)
At close: Feb 13, 2024, 9:59 PM
Theseus Pharmaceuticals Income Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | 22.51K | 158.71K | 155.15K | 152K | 148.96K | n/a | n/a | n/a | n/a | n/a | n/a |
Gross Profit | -22.51K | -158.71K | -155.15K | -152K | -148.96K | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Income | -16.4M | -17.59M | -17.05M | -15.48M | -15.95M | -12.08M | -10.58M | -8.66M | -7.37M | -6.81M | -4.49M |
Interest Income | 2.9M | 2.78M | n/a | 1.76M | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Pretax Income | -13.5M | -14.8M | -14.59M | -13.72M | -14.74M | -11.65M | -10.5M | -8.66M | -7.37M | -6.81M | -4.47M |
Net Income | -13.5M | -14.8M | -12.12M | -15.43M | -13.54M | -11.22M | -10.41M | -8.66M | -7.37M | -6.81M | -4.47M |
Selling & General & Admin | 4.88M | 4.67M | 4.65M | 5.1M | 4.53M | 4.74M | 4.03M | 3.64M | 2.38M | 2.33M | 664K |
Research & Development | 11.52M | 12.92M | 12.4M | 10.38M | 11.42M | 7.34M | 6.55M | 5.02M | 5M | 4.49M | 3.83M |
Other Expenses | n/a | n/a | n/a | n/a | n/a | n/a | 82K | 3K | 2K | 7K | 16K |
Operating Expenses | 16.4M | 17.59M | 17.05M | 15.48M | 15.95M | 12.08M | 10.58M | 8.66M | 7.37M | 6.81M | 4.49M |
Interest Expense | n/a | n/a | n/a | 1.72M | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 16.4M | 17.59M | 17.05M | 15.48M | 15.95M | 12.08M | 10.58M | 8.66M | 7.37M | 6.81M | 4.49M |
Income Tax Expense | -22K | n/a | -2.47M | 1.72M | -1.2M | -431K | -82K | -3K | -2K | -7K | -16K |
Shares Outstanding (Basic) | 43.8M | 43.74M | 42.37M | 38.7M | 38.59M | 38.42M | 38.25M | 35.88M | 35.86M | 35.86M | 25.37M |
Shares Outstanding (Diluted) | 43.8M | 43.74M | 42.37M | 38.7M | 38.59M | 38.42M | 38.25M | 35.88M | 35.86M | 35.86M | 25.37M |
EPS (Basic) | -0.31 | -0.34 | -0.29 | -0.4 | -0.35 | -0.29 | -0.27 | -0.24 | -0.21 | -0.19 | -0.18 |
EPS (Diluted) | -0.31 | -0.34 | -0.29 | -0.4 | -0.35 | -0.29 | -0.27 | -0.24 | -0.21 | -0.19 | -0.18 |
EBITDA | -16.4M | -17.57M | -17.05M | -13.75M | -15.93M | -12.07M | -10.58M | -8.66M | -7.37M | -6.81M | -4.49M |
EBIT | -16.4M | -17.59M | -17.05M | -12M | -15.95M | -12.08M | -10.58M | -8.66M | -7.37M | -6.81M | -4.49M |
Depreciation & Amortization | 22K | 21K | 20K | 20K | 18K | 11K | 1K | 1K | 2K | 55.81K | 1K |